





3

Methods Prospective, single-center randomized controlled trial, n=130 Ambulatory robotic prostatectomy patients, < 80 years, ASA I-III Randomized to deep vs moderate NMB Deep NMB TOF = 0 Moderate NMB PTC = 1-2 Monitoring: quantitative Neuromuscular Transmission (NMT) device (GE Healthcare) SAMBA 2025 ANNUAL MEETING • MAY 2-4, 2025 • ARIZONA BILTMORE

4

6

Outcomes & Analysis Surgical conditions, intraoperative opioids, operating time, EBL, PONV, shoulder pain BMI, surgeon-level random effects Secondary exploratory analysis Postoperative pair SAMBA 2025 ANNUAL MEETING - MAY 2-4, 2025 - ARIZONA BILTMORE - PHOENIX, AZ 🛛 🚳

Results Deep NMB (n=67), Moderate NMB (n=63) Spearman r= -0.018; p=0.8 Primary outcomes 1% lower IAP in deep group (p=0.5) 25% lower postop pain in deep group (p=0.2)

→ neither statistically significant Secondary Outcomes No significant differences except intraoperative IV MME (-0.9 in deep; p=0.048) Exploratory Analysis (presented separately) Findings comparable to primary analysis SAMBA 2025 ANNUAL MEETING - MAY 2-4, 2025 - ARIZONA BILTMORE - PHOENIX, AZ 🛛

5

1

Conclusions & Future Directions



- Quantified deep NMB had no effect on IAP, postoperative pain & all but one secondary outcome
- Low overall need for analgesics/antiemetics
- Explore in other surgical populations
- Technical challenges with quantitative NMB monitoring (presented separately)
- Studies using newer-generation monitors warranted



Contact information

Marielle P Soeprono, MS CRNA

Email: PalonM@mskcc.org

SAMBA 2025 ANNUAL MEETING - MAY 2-4, 2025 - ARIZONA BILTMORE - PHOENIX, AZ

7